The new Sheffield risk and benefit tables for the elderly

QJM: An International Journal of Medicine

Volumn 104, Issue 1, 2011, Pages 3-12

  Weatherley, N D ^a   Jackson, P R ^b  

^a South Yorkshire Deanery   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; ANTIHYPERTENSIVE THERAPY; CALCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; GENDER; GERIATRIC ASSESSMENT; HUMAN; HYPERTENSION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHEFFIELD RISK AND BENEFIT TABLE; SMOKING; STATISTICAL MODEL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 78650335761     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq167     Document Type: Review

References (24)

1. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-62.
2. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346:1467-71.
3. Conroy RM, Pyö rälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
4. Joint British Societies of British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society and The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl V):v1-53.
5. Simons LA, Simons J, Friedlander Y, McCallum J, Palaniappan L. Risk factors for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Med J Aust 2003; 178:113-6.
6. Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR. Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation. J Hypertens 2001; 19:691-6.
7. Gueyffier F, Boissel JP, Pocock S, Boutitie F, Coope J, Cutler J, et al. Identification of risk factors in hypertensive patients: contribution of randomised controlled trials through an individual patient database. Circulation 1999; 100:e88-94.
8. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age and over. N Engl J Med 2008; 358:1887-98.
9. Wittes J, Davis B, Berge K, Cohen JD, Grimm RH, Hawkins CM, et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: Analysis. Hypertension 1991; 17(3 Suppl.):162-7.
10. DH.gov.uk [Internet page]. UK: Quality and Outcomes Framework (QOF); 2009. [http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/QOF/index .htm.] Accessed 18 April 2009.
11. Lee DR, Swift CG, Jackson SHD. Twenty-four-hour ambulatory blood pressure monitoring in healthy elderly people: reference values. Age Aging 1995; 24:91-5.
12. Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N, et al. Serum lipid concentration in relation to anthropometric indices of central and peripheral fat distribution in 20,021 British men and women: Results from the EPIC-Norfolk population-based cohort study. Atherosclerosis 2006; 189:420-7.
13. DH.gov.uk [Internet page]. Health Survey for England; 2009 [http://www.dh.gov.uk/en/Publicationsandstatistics/PublishedSurvey/HealthSurveyForEngland/DH_632.] Accessed 18 April 2009.
14. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-16.
15. Office for National Statistics (2005). Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2004 (Series DH2 no.31). London (Office for National Statistics), Her Majesty's Stationery Office.
16. Insua JT, Sacks HS, Lau T-S, Lau J, Reitman D, Pagano D, et al. Drug Treatment of hypertension in the elderly. A meta-analysis. Ann Intern Med 1994; 121:355-62.
17. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28:946-50.
18. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomised controlled trials. JAMA 1999; 282:2340-6.
19. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. Br Med J 2003; 327:1267.
20. ABS.gov.au [homepage on the Internet]. Australian Bureau of Statistics, 2009 [http://www.abs.gov.au/websitedbs/D3310114.nsf/home/home?opendocument?utm_id=GT.] Accessed 18 April 2009.
21. de Bruyne MC, Kors JA, Hoes AW, Klootwijk P, Dekker JM, Hofman A, et al. Both decreased and increased heart rate variability on the standard 10-second electrocardiogram predict cardiac mortality in the elderly. The Rotterdam Study. Am J Epidemiol 1999; 150:1282-8.
22. Mazza A, Pessina AC, Gianluca P, Tikhonoff V, Pavei A, Casiglia E. Pulse pressure: an independent predictor of coronary and stroke mortality in elderly females from the general population. Blood Press 2001; 10:205-11.
23. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women. The Cardiovascular Health Study. Circulation 2005; 112:25-31.
24. Wallis EJ, Ramsay LE, Haq IU, Ghahramani P, Jackson PR, Rowland-Yeo K, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. Br Med J 2000; 320:671-6.